Product logins

Find logins to all Clarivate products below.


Chronic Cough | Treatment Algorithms: Claims Data Analysis | US | 2020

Chronic cough could be a result of underlying diseases (e.g., asthma, GERD), a complication of drug therapy (e.g., ACE inhibitors), or have an idiopathic feature without a clear underlying cause. Treatment typically begins with drugs targeting the suspected underlying disease; if there is no improvement, different classes of drugs might then be tried to treat the cough and identify its etiology. Physicians also prescribe antitussive agents to manage the disturbing cough symptoms. The sequential and empirical approach in treating chronic cough makes the treatment landscape complex.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed chronic cough patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed chronic cough patients?
  • What percentage of chronic cough patients receive drug therapy within 12 months of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 12 months of diagnosis?
  • What percentage of chronic cough patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

GEOGRAPHIES

United States

REAL WORLD DATA

Longitudinal patient-level claims data analysis

KEY DRUGS COVERED

Antitussive agents, PPIs, SABAs

KEY ANALYSIS PROVIDED

Brand / therapy usage across longitudinal patient sample

Newly diagnosed patient analysis

Treatment initiation and progression

Line of therapy analysis

Combination therapy analysis

Source of business for recently treated patients

Persistency and compliance analysis

Product-level patient flowcharts

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Related Market Assessment Reports

Report
Alzheimer’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alzheimer’s Disease (US)
The treatment of early Alzheimer’s disease (AD) is being transformed by the launches of Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s donanemab (Kisunla), and additional disease-…
Report
Parkinson’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Parkinson’s Disease (US)
Parkinson’s disease (PD) is a progressive neurodegenerative condition that is treated chronically with prescription therapies from an array of mechanistically distinct drug classes, including…
Report
Psoriasis – Access & Reimbursement – Access & Reimbursement – Psoriasis (US)
The U.S. psoriasis treatment landscape is rapidly evolving, with newer, more effective therapies increasing competition for favorable MCO coverage, further intensified by the introduction of…
Report
Attention-Deficit-Hyperactivity Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric ADHD (US)
ADHD is a common pediatric neurodevelopmental disorder, with diagnosis rates supported by increased awareness and routine screening; however, symptoms often persist into adulthood. Longacting…
Report
Obesity – Current Treatment – Current Treatment: Physician Insights – GLP-1 Receptor Agonist Products (US)
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) products like Novo Nordisk’s SC semaglutide (Ozempic / Wegovy) and Eli Lilly’s tirzepatide (Mounjaro / Zepbound) have seen significant growth…